← FDA DRUG APPROVALS

FDA ANDA · ANDA202490

RIZATRIPTAN BENZOATE

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA202490
TYPE
ANDA
ORIGINAL APPROVAL
2012-12-31
LATEST ACTION
2020-10-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 5MG BASE · TABLET · ORAL
RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET · ORAL

Approval history

2020-10-06Labeling · Supplement 8 · standardAP
2015-11-09Labeling · Supplement 4 · standardAP
2012-12-31UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →